Ayala Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Ayala receives Nasdaq delisting notice for MVPHS non-compliance; 180-day cure until May 2023

Ayala Pharmaceuticals, Inc.

Nasdaq notified Ayala on Nov 18, 2022 of non-compliance with minimum $5M MVPHS requirement.
Trading of AYLA common stock on Nasdaq Global Market is unaffected during the cure period.
Ayala has until May 17, 2023 to regain compliance; MVPHS must close at $5M+ for 10 consecutive days.
Possible remedies include transferring to Nasdaq Capital Market or appealing a delisting notice.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Ayala Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(1)(C)

Exact text from the filing

November 18, 2022, Ayala Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is no longer in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $5,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(1)(C) (the “MVPHS Requirement”). The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market and the Company’s common stock will continue to trade under the s

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-22-292007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.